SEC Filing Summary: Aerpio Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aerpio Pharmaceuticals, Inc. on August 8, 2017. The report addresses a corporate event regarding the trading status of the company's common stock. Note: The request metadata references "Whitehawk Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Aerpio Pharmaceuticals, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to reporting a specific corporate event under Item 8.01.
Material Changes
The primary material change reported is the clearance of the Company's common stock for trading on the OTC Market Group's OTCQB Market quotation system. Trading commenced under the ticker symbol "ARPO" effective at the market open on August 8, 2017.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or a discussion of risks and contingencies. It references a press release (Exhibit 99.1) for further details but does not include the text of that release within this document.
Investor Verification Checklist
- Verify the current ticker symbol "ARPO" and its listing on the OTCQB Market.
- Review the attached press release (Exhibit 99.1) for context on the delisting or transfer to the OTC market.
- Confirm the company's current financial status through its most recent 10-K or 10-Q filings, as this 8-K contains no financial data.
- Check for any subsequent filings regarding the company's name change or merger, given the discrepancy between the request metadata (Whitehawk) and the filing (Aerpio).